News | February 05, 2026
AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The new service delivers end-to-end support, managing every stage of an epigenomics project
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Subscribe To Our Newsletter & Stay Updated
